Silicosis

Silicosis is an irreversible occupational lung disease caused by inhalation of respirable crystalline silica (silicon dioxide) dust, resulting in progressive nodular pulmonary fibrosis. It is the world's most prevalent occupational lung disease and has no cure. Once considered a disease of the past in developed countries, silicosis is experiencing a resurgence driven by engineered stone (quartz) countertop fabrication, which has created a new epidemic predominantly affecting young immigrant workers. Silica is classified as a Group 1 human lung carcinogen by IARC. The ED physician will encounter silicosis patients presenting with progressive dyspnea, respiratory infections (especially tuberculosis), pneumothorax, and acute respiratory failure.

Background

• Crystalline silica (quartz) is one of the most abundant minerals on earth; occupational exposure occurs when silica-containing materials are cut, ground, drilled, or blasted, generating respirable dust (<10 µm)
• High-risk occupations: Mining, quarrying, tunneling, sandblasting, construction (cutting/drilling concrete, brick, stone), foundry work, glass manufacturing, ceramics/pottery, gemstone cutting, dental laboratory work, stone countertop fabrication
• The engineered stone epidemic:
  • Engineered stone ("quartz") countertops contain >90% crystalline silica (vs. granite ~30–50%, marble <10%)
  • US imports of engineered stone rose 800% from 2010 to 2018; now the most popular countertop material in the US
  • By November 2024: 219 cases identified in California alone, including at least 14 deaths and 26 lung transplantations; median age 45; nearly all Latino immigrants
  • Australia banned engineered stone effective July 2024 after 21% of screened workers were found to have silicosis
  • Many workers present with accelerated disease — severe fibrosis after only 5–15 years of exposure, far more aggressive than traditional chronic silicosis
• Pathogenesis: Inhaled silica particles reach the terminal bronchioles and alveoli → engulfed by alveolar macrophages → macrophages cannot clear the particles → macrophage death releases silica and inflammatory mediators → cycle of chronic inflammation → fibroblast activation → irreversible nodular fibrosis
• Three forms of silicosis:
  • Chronic (classic) silicosis: Most common; latency 10–30+ years after moderate exposure; may be simple (small nodules) or complicated (progressive massive fibrosis/PMF)
  • Accelerated silicosis: Higher exposure; latency 5–10 years; clinically and pathologically similar to chronic silicosis but progresses faster; this is the predominant form in engineered stone workers
  • Acute silicosis (silicoproteinosis): Intense exposure over weeks to months; clinically resembles pulmonary alveolar proteinosis; rapidly progressive; often fatal
• Associated conditions:
  • Tuberculosis: Patients with silicosis have a ~30-fold increased risk of TB (silicotuberculosis); even silica-exposed workers without silicosis have 3× the risk
  • Lung cancer: Crystalline silica is IARC Group 1 carcinogen
  • Autoimmune diseases: Increased risk of rheumatoid arthritis (Caplan syndrome — silicosis + rheumatoid nodules), scleroderma, SLE, ANCA-associated vasculitis
  • Chronic renal disease
  • COPD (emphysema, chronic bronchitis) — independent of smoking
  • Spontaneous pneumothorax
• OSHA PEL: 50 µg/m³ (8-hour TWA); updated in 2016

Clinical Features

Chronic silicosis:

• Often asymptomatic for years — symptoms lag behind radiographic disease
• Progressive exertional dyspnea (most common symptom)
• Chronic dry cough (may become productive with superimposed infection)
• Fatigue, reduced exercise tolerance
• Physical exam: May be normal early; bibasal inspiratory crackles; advanced disease: signs of right heart failure (cor pulmonale), clubbing (uncommon unless complicated by other ILD or malignancy)
• Progressive massive fibrosis (PMF): Coalescence of nodules into large opacities (>1 cm); marked dyspnea, severe restriction, respiratory failure

Accelerated silicosis (engineered stone):

• Younger patients (median ~45 years in US cases; some as young as late 20s)
• More rapid progression to PMF and respiratory failure
• Many present with advanced disease at diagnosis — nearly half in the California cohort

Acute silicosis (silicoproteinosis):

• Onset weeks to few years after intense exposure
• Rapidly progressive dyspnea, cough, weight loss, fatigue
• May present with acute respiratory failure
• Resembles pulmonary alveolar proteinosis clinically and radiographically (bilateral alveolar filling pattern)
• Poor prognosis; often fatal

ED presentations:

• Progressive dyspnea with occupational exposure history
• Superimposed respiratory infection (always consider TB — silicotuberculosis)
• Spontaneous pneumothorax
• Acute respiratory failure (acute silicosis or end-stage chronic disease)
• Hemoptysis (from PMF cavitation, TB, or broncholithiasis)
• Incidental finding of bilateral upper-lobe nodules on CT obtained for another reason

Differential Diagnosis

• Tuberculosis (may coexist with silicosis — silicotuberculosis; cavitary lesions in PMF raise concern for TB superinfection)
• Sarcoidosis (bilateral hilar lymphadenopathy + upper-lobe nodules; noncaseating granulomas; no occupational exposure)
• Chronic beryllium disease (requires BeLPT to distinguish; identical imaging possible)
• Other pneumoconioses: Asbestosis (basal-predominant fibrosis + pleural plaques), coal workers' pneumoconiosis (similar imaging but different exposure)
• Idiopathic pulmonary fibrosis (basal-predominant; UIP pattern; no occupational exposure)
• Hypersensitivity pneumonitis (exposure history differs; centrilobular nodules and air trapping)
• Pulmonary alveolar proteinosis (for acute silicosis — "crazy-paving" pattern)
• Metastatic disease or lymphoma (for PMF masses)
• Lung cancer (may coexist; silica is carcinogenic)
• Fungal infections (histoplasmosis, coccidioidomycosis)

Evaluation

Workup

History — critical:

• Detailed occupational history: All current and prior jobs; specifically ask about mining, construction, sandblasting, foundry, ceramics, glass, stone cutting/fabrication/installation, demolition, tunneling, dental lab work
• Ask specifically about stone countertop work — engineered stone/quartz/artificial stone fabrication, cutting, polishing, installation; many workers may not realize this is a silica-exposure occupation
• Duration of exposure, use of respiratory protection, wet vs. dry cutting methods
• Smoking history (compounds risk; assess for concomitant COPD)
• TB risk factors and prior testing
• Immigration status may affect healthcare access — provide resources regardless of documentation status

Laboratory (ED):

• CBC, CMP
• ABG/VBG: Hypoxemia; exercise desaturation in moderate disease
• Sputum for AFB smear, culture, and mycobacterial PCR if TB suspected (silicotuberculosis)
• Annual TB screening is recommended for all silica-exposed patients (tuberculin skin test or IGRA) — initiate if not recently done
• No specific serum biomarker for silicosis
• Procalcitonin, blood cultures if concurrent infection suspected
• BNP/NT-proBNP if cor pulmonale or right heart failure suspected

Imaging:

Chest X-ray:

• Small round opacities in the upper and middle lung zones — the classic finding; graded by ILO classification (profusion and size: p, q, r)
• Eggshell calcification of hilar lymph nodes — not pathognomonic but highly suggestive (~5–10% of cases)
• Progressive massive fibrosis (PMF): Large opacities (>1 cm), typically in upper lobes, often bilateral and symmetric; may cavitate (raises concern for TB, anaerobic infection, or necrosis)
• Hilar and mediastinal lymphadenopathy
• Compensatory emphysema peripheral to conglomerate nodules
• Acute silicosis: Bilateral alveolar/ground-glass pattern resembling pulmonary edema or alveolar proteinosis; Kerley B lines; pleural effusions may occur

HRCT — more sensitive than CXR:

• Small centrilobular and subpleural nodules, upper-zone predominant
• Nodule coalescence in PMF
• Associated emphysema
• Ground-glass opacities (acute or accelerated forms)
• Mediastinal/hilar lymphadenopathy (may show eggshell calcification)
• HRCT can detect silicosis when CXR is normal — CXR sensitivity for silicosis is only 35–48% compared to HRCT

PFTs (outpatient):

• May be normal in simple chronic silicosis
• Restrictive pattern most common (reduced FVC, TLC)
• Obstructive pattern may be seen (especially with concurrent COPD/emphysema)
• Mixed restrictive-obstructive pattern in advanced disease
• Reduced DLCO

Diagnosis

• Three elements:
  • (1) History of sufficient occupational silica exposure
  • (2) Chest imaging consistent with silicosis (CXR or HRCT)
  • (3) Exclusion of other conditions that better explain the findings
• Tissue biopsy is generally NOT required — clinical-radiographic diagnosis is sufficient in most cases
• Biopsy (transbronchial or surgical) if diagnosis is uncertain: concentric whorled collagenous nodules (silicotic nodules) with birefringent particles under polarized light
• Always exclude TB — sputum AFB, cultures, +/- PCR in any patient with silicosis and new symptoms, cavitary lesions, or fever
• In the ED: Consider silicosis in any patient with bilateral upper-lobe nodularity or fibrosis + occupational exposure history; ensure appropriate referral even if the patient presents for an unrelated complaint

Management

There is no cure for silicosis — management is entirely supportive and preventive

1. Remove from further silica exposure — the most important intervention; though disease may progress even after exposure ceases

2. ED management:

• Supplemental O2 to maintain SpO2 ≥90%
• Bronchodilators (albuterol, ipratropium) — may benefit patients with obstructive component; ~25% have bronchodilator responsiveness
• Non-invasive ventilation or intubation for respiratory failure
• Treat superimposed infection aggressively
• If TB suspected: Respiratory isolation, sputum AFB ×3, initiate empiric TB therapy if high clinical suspicion (silicotuberculosis has higher treatment failure and mortality than TB alone)
• Chest tube for pneumothorax
• Treat cor pulmonale/right heart failure if present (diuretics, supplemental O2)

3. TB management in silicosis:

• Latent TB infection: Treatment is strongly recommended in all silicosis patients with positive TST or IGRA, regardless of age
• Active TB: Standard anti-TB regimens; may require prolonged treatment courses due to higher treatment failure rates in silicotuberculosis
• Screen annually with TST or IGRA

4. Acute silicosis (silicoproteinosis):

• Whole lung lavage has been used (similar to treatment for pulmonary alveolar proteinosis); clinical benefit not well established
• Systemic corticosteroids — limited evidence; may provide modest benefit
• Prognosis is poor regardless of treatment

5. Long-term management (coordinate with pulmonology/occupational medicine):

• Smoking cessation (mandatory — compounds injury and cancer risk)
• Pulmonary rehabilitation
• Supplemental O2 for chronic hypoxemia
• Vaccinations: Annual influenza, pneumococcal, COVID-19
• Lung cancer screening (silica is Group 1 carcinogen)
• Lung transplantation for end-stage disease (PMF with respiratory failure); increasing demand from engineered stone workers
• No proven antifibrotic therapy for silicosis (nintedanib and pirfenidone have not been specifically studied in silicosis)

6. Reporting:

• Silicosis is a reportable occupational disease in most jurisdictions — notify public health/occupational health authorities
• Document occupational exposure history thoroughly (may be needed for workers' compensation claims)

Disposition

• Admit:
  • Acute respiratory failure
  • Suspected silicotuberculosis (respiratory isolation pending AFB results)
  • Acute silicosis with progressive hypoxemia
  • Pneumothorax requiring chest tube
  • Hemoptysis requiring evaluation (PMF cavitation, TB, malignancy)
  • Severe exacerbation of known silicosis (infection, cor pulmonale)
• Discharge with close follow-up:
  • Stable known silicosis with mild respiratory symptoms at baseline
  • New suspected silicosis in stable patient — arrange:
    • Pulmonology and/or occupational medicine referral within 1–2 weeks
    • HRCT if not performed (CXR alone has low sensitivity)
    • PFTs with DLCO
    • TB screening (TST or IGRA) if not recently performed
  • Discharge counseling:
    • Avoid further silica exposure — discuss with employer; may require job change or engineering controls (wet cutting, ventilation, respirators)
    • Return for worsening dyspnea, fever, hemoptysis, chest pain
    • Smoking cessation
    • Ensure vaccinations are current
    • Report to occupational health for workplace evaluation and coworker screening
    • For engineered stone workers: The LAM Foundation and occupational health resources may provide guidance; connect with legal resources if appropriate as this is an area of active litigation and compensation

See Also

• Asbestosis
• Beryllium toxicity
• Pneumoconiosis
• Tuberculosis
• Pulmonary alveolar proteinosis
• Sarcoidosis
• Hypersensitivity pneumonitis
• Heavy metal toxicity

External Links

• Silicosis — StatPearls
• Silicosis — Merck Manual Professional
• Respirable Crystalline Silica — OSHA
• Silica — NIOSH/CDC
• Deadly Countertops: Engineered Stone Workers (AJRCCM 2025)
• Managing Silicosis in the United States (CHEST Pulmonary 2024)